Last update 21 Nov 2024
CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Stem cell therapy |
Synonyms- |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)Evaluating the safety of autologous intra papillary muscle injection of bone marrow stem cell in patients with up to moderate ischemic mitral regurgitation: A Phase II clinical trial
Intramyocardial Transplantation of Bone Marrow Stem Cells for Improvement of Post-infarct Myocardial Regeneration in Addition to CABG Surgery: a Controlled, Prospective, Randomized, Double Blinded Multicenter Trial (PERFECT)
100 Clinical Results associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)
Login to view more data
100 Translational Medicine associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)
Login to view more data
100 Patents (Medical) associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)
Login to view more data
100 Deals associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Coronary Disease | Phase 3 | DE | 15 Jul 2020 | |
| Left ventricular systolic dysfunction | Phase 3 | US | 31 Jan 2010 | |
| Neoplasms | Phase 3 | DE | 31 Jul 2009 | |
| Ventricular Arrhythmia | Phase 3 | DE | 31 Jul 2009 | |
| Myocardial Infarction | Phase 3 | DE | 01 Jul 2009 | |
| Angina Pectoris | Phase 3 | DE |  Miltenyi Biomedicine GmbHStartup | 01 Apr 2007 |
| Coronary Artery Disease | Phase 3 | DE | Miltenyi Biomedicine GmbHStartup | 01 Apr 2007 |
| Coronary Artery Disease | Phase 3 | DE | Miltenyi Biomedicine GmbHStartup | 01 Apr 2007 |
| Heart Failure | Phase 3 | DE | Miltenyi Biomedicine GmbHStartup | 01 Apr 2007 |
| Old myocardial infarction | Phase 3 | DE | Miltenyi Biomedicine GmbHStartup | 01 Apr 2007 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free